Evaluating depressive symptoms, BDNF Val66Met, and APOE-ε4 as moderators of response to computerized cognitive training in heart failure

• Published in: Heart & lung 2023-05, Vol.59, p.146-156
• Main Authors: Pressler, Susan J., Jung, Miyeon, Giordani, Bruno, Titler, Marita G., Gradus-Pizlo, Irmina, Lake, Kittie Reid, Wierenga, Kelly L., Clark, David G., Perkins, Susan M., Smith, Dean G., Mocci, Evelina, Dorsey, Susan G.
• Format: Article
• Language: English
• Subjects: Activities of Daily Living; Apolipoproteins; Apolipoproteins E; Brain-Derived Neurotrophic Factor; Cognitive Training; Computerized cognitive training; Congestive heart failure; Depression - therapy; Health-related quality of life; Heart failure; Heart Failure - therapy; Humans; Memory; Quality of Life
• ISSN: 0147-9563; 1527-3288
• DOI: 10.1016/j.hrtlng.2023.02.002

·Depressive symptoms, BDNF Val66Met, and APOE-ε4 were not significant moderators.·Global cognition, gender, age, and HF severity were not significant moderators.·Studies are needed to elucidate biological mechanisms of cognitive dysfunction in HF and test novel interventions to improve memory in patients. Depressive symptoms, brain-derived neurotrophic factor (BDNF) Val66Met, and apolipoprotein (APOE)-ε4 may moderate response to computerized cognitive training (CCT) interventions among patients with heart failure (HF). The purpose of this study was to examine moderators of intervention response to CCT over 8 months among patients with HF enrolled in a 3-arm randomized controlled trial. Outcomes were memory, serum BDNF, working memory, instrumental activities of daily living (IADLs), and health-related quality of life (HRQL). 256 patients with HF were randomized to CCT, computerized crossword puzzles active control, and usual care control groups for 8 weeks. Data were collected at enrollment, baseline, 10 weeks, and 4 and 8 months. Mixed effects models were computed to evaluate moderators. As previously reported, there were no statistically significant group by time effects in outcomes among the 3 groups over 8 months. Tests of moderation indicated that depressive symptoms and presence of BDNF Val66Met and APOE-ε4 were not statistically significant moderators of intervention response in outcomes of delayed recall memory, serum BDNF, working memory, IADLs, and HRQL. In post hoc analysis evaluating baseline global cognitive function, gender, age, and HF severity as moderators, no significant effects were found. HF severity was imbalanced among groups (P = .049) which may have influenced results. Studies are needed to elucidate biological mechanisms of cognitive dysfunction in HF and test novel interventions to improve memory, serum BDNF, working memory, IADLs and HRQL. Patients may need to be stratified or randomized by HF severity within intervention trials.